Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
#1QWithCNBCTV18 | Dr Reddy's, #Cipla down more than 1% each post Q1 results https://t.co/qyH4Kg0LvI
Dr. Reddy's Laboratories: Revenue up 14% to ₹7,672.7 crore, better than estimates. EBITDA margin at 28.2%, better than estimate of 27.4% but lower than 31.7% from last year but improve sequentially. US sales up 20% year-on-year and 18% sequentially to ₹3,846.2 crore. Europe…
Multi Commodity Exchange of India Q1 (Consolidated QoQ) Profit increases 26.2% to Rs 110.9 crore Vs Rs 87.9 crore Revenue rises 29.4% to Rs 234.4 crore Vs Rs 181.1 crore
Dr. Reddy's Laboratories Ltd. announced its unaudited financial results for Q1FY25, the quarter ended June 30, 2024. The company's profit after tax fell 0.8% year-on-year to Rs 1,392 crore, while revenue increased by 14% to ₹7,672.7 crore. The EBITDA rose by 1.06% to Rs 2,159.9 crore, though the EBITDA margin dropped to 28.2% from 31.7% last year but was better than the estimate of 27.4%. US sales saw a significant increase of 20% year-on-year and 18% sequentially, reaching Rs 3,846.2 crore. Additionally, Dr. Reddy's announced its first-ever stock split in 20 years.
